OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
तुलना करने के लिए मीट्रिक्स | 4564 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4564पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −7.5x | −7.0x | −0.6x | |
PEG अनुपात | −0.26 | −0.31 | 0.00 | |
क़ीमत/बुक | 9.2x | 4.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 10.8x | 69.2x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 15.1% | 51.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 16.0% | 8.3% | अनलॉक करें |